Revelation Bio shareholders approve reverse split up to 1:250; Nevada reincorporation fails despite 89% support

REVELATION BIOSCIENCES, INC.

Reverse stock split authorized at ratio 1:2 to 1:250, board to set exact ratio within one year.
Issuance of common stock under May 2025 Class H Warrants above 20% exchange cap approved.
Reincorporation from Delaware to Nevada failed (89% of votes cast in favor, but not enough outstanding shares).
Lakhmir Chawla elected Class C director; advisory votes on exec compensation and frequency (3 years) passed.
Baker Tilly US ratified as auditor for FY2025; CEO presentation given but details not disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.